BioControl
This article was originally published in The Gray Sheet
Executive Summary
Raises $12 mil. in capital from offshore investors. The funds will be used for manufacturing operations for the Diasensor 1000 non-invasive glucose monitor sensor and for "other projects." BTI will manufacture the glucose monitor sensors under an agreement with Diasense, which will market the sensors worldwide ("The Gray Sheet" Jan. 10, In Brief). Production, slated for late spring, will begin at a rate of 1,000 to 2,000 per month as the firm gears up capacity. Biocontrol CEO Fred Cooper noted that "there has been some concern as to the company's financial condition over the years," but the exec asserted that Biocontrol "is in the strongest cash position in its history, and we can now complete many of the objectives that we have so vigorously worked to accomplish"
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.